title: Preclinical risk assessment of drug-induced hypo- and hyperprolactinemia.
abstract: Drug-induced changes in prolactin signaling may obscure interpretation of preclinical toxicological endpoints. However, with informed consideration, classic hallmarks of hypo-/hyperprolactinemia can be recognized in short- and long-term rodent bioassays. Findings can be supported and expanded with additional in vivo and in vitro datasets. When taken together with human epidemiological evidence pertaining to the consequences of drug-induced hypo-/hyperprolactinemia, such findings permit both an analysis of human relevance and an assessment of human risk.
authors: Pathology Department, Safety Assessment, Astrazeneca Pharmaceuticals, Alderley Park, Cheshire, SK10 4TG, UK. adam.hargreaves@astrazeneca.com
authors: Adam
authors: A
authors: Hargreaves
authors: Johannes
authors: J
authors: Harleman
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced* / Q000473:pathology; D011388:Prolactin / Q000097:blood*; D018570:Risk Assessment
chemical_list: D011388:Prolactin